drugset / Trial / NCT07102342
This Clinical Trial is Designed to Evaluate the Safety, Tolerability, Feasibility and Preliminary Efficacy of NouvNeu001 (Human Dopaminergic Progenitor Cells Injection) in Patients With Parkinson's Disease.
NaSingle-groupOpen-labelTreatment
Summary
This is a phase 1/2 clinical study to evaluate the safety, tolerability, feasibility, and preliminary efficacy of NouvNeu001 in patients with advanced Parkinson's Disease.
Timeline
- Start
- 2026-01-12
- Primary completion
- 2027-09
- Completion
- 2032-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Human Dopaminergic Progenitor Cells | Cell therapy | — | Other |